NCT04290546 2026-02-27CIML NK Cell in Head & Neck CancerDana-Farber Cancer InstitutePhase 1 Completed11 enrolled
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT06161545 2025-10-20Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting40 enrolled